Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Our research team asked a simple question: could we turn a routine ultrasound scan into a quick, reliable way to measure ...

The management of acute limb ischemia requires a thorough understanding of the anatomy of the arterial occlusion and the open surgical and percutaneous options for restoring limb perfusion.

Why do rural adults and racial and ethnic minorities with vascular disease get major leg amputations more often? A new study ...

Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the ...

Breakthrough procedure reduces amputation risk for patients with Chronic Limb-Threatening Ischemia We're not only ...

Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company ...

Watch the video Click the White paper STENTiT Enrolls First Patient in Clinical TrialEvaluating a Novel Stent with ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses, according to new ...

In a groundbreaking medical achievement, Dr. Ahmed Amir, vascular surgery consultant at Jaber Al-Ahmad Hospital, has ...

STENTiT implanted its Resorbable Fibrillated Scaffold in the first patient enrolled in the VITAL-IT 1 study evaluating the device for CLTI.